Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nano Dimension Ltd - ADR (NNDM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Nano Dimension Ltd - ADRTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Nano Dimension Ltd - ADR vs Regeneron Pharmaceuticals Inc — how do they compare? Nano Dimension Ltd - ADR trades at $1.49 (market cap $322.08M), while Regeneron Pharmaceuticals Inc trades at $673.67 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 218.8× Nano Dimension Ltd - ADR's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Nano Dimension Ltd - ADR pays none. Which is the better fit depends on your goals.

NNDMREGN
Market Cap
$322.08M$70.47B
Sector
TechnologyHealth
52-Week High
$2.14$812.27
52-Week Low
$1.21$545.46
Enterprise Value
-$87.26M$64.42B
Dividend Yield
0.56%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Nano Dimension Ltd - ADR

Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.

Read more on NNDM

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN